Chiral Nanoceramics

The study of different chiral inorganic nanomaterials has been experiencing rapid growth during the past decade, with its primary focus on metals and semiconductors. Ceramic materials can substantially expand the range of mechanical, optical, chemical, electrical, magnetic, and biological properties of chiral nanostructures, further stimulating theoretical, synthetic, and applied research in this area. An ever‐expanding toolbox of nanoscale engineering and self‐organization provides a chirality‐based methodology for engineering of hierarchically organized ceramic materials. However, fundamental discoveries and technological translations of chiral nanoceramics have received substantially smaller attention than counterparts from metals and semiconductors. Findings in this research area are scattered over a variety of sources and subfields. Here, the diversity of chemistries, geometries, and properties found in chiral ceramic nanostructures are summarized. They represent a compelling materials platform for realization of chirality transfer through multiple scales that can result in new forms of ceramic materials. Multiscale chiral geometries and the structural versatility of nanoceramics are complemented by their high chiroptical activity, enantioselectivity, catalytic activity, and biocompatibility. Future development in this field is likely to encompass chiral synthesis, biomedical applications, and optical/electronic devices. The implementation of computationally designed chiral nanoceramics for biomimetic catalysts and quantum information devices may also be expected.Chiral nanoceramics are emerging as a remarkably active area of chiral research. It is still in its infant stage and is thus full of challenges and opportunities. Recent advances in the diversity of chemistries, geometries, and properties of chiral ceramic nanostructures are reviewed. An outlook of synthesis, computational methods, and emerging applications of chiral nanoceramics is presented.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/163453/2/adma201906738_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/163453/1/adma201906738.pd

Serumproteinbindung von ACTH

3H- 1–23-Corticotropin wurde an Dextrangel (Sephadex G-25) gebunden und konnte durch Serumproteine, Albumin oder 0,1 N HCl eluiert werden. Mittels Dextrangelfiltration wurde gefunden, daß3H-ACTH kompetitiv an Serumproteine (Albumin) und Dextrangel gebunden wurde. Auch für natürliches Schweine-ACTH und endogenes ACTH in Patientenplasma (Adrenalektomie) wurde mittels biologischer ACTH-Bestimmung die Bindung von ACTH an Proteine bestätigt.3H- 1–23 corticotropin was bound to dextran gel (sephadex G-25) and was eluted by either serum proteins, albumin or 0.1 N HCl. Competitive binding of3H-ACTH to serum proteins (albumin) and dextran gel was shown by dextran gel filtration. Likewise natural ACTH (pig) and endogenous ACTH from plasma of an adrenalectomized patient were shown to be partly protein bound using biological ACTH-assay

TRH: Pathophysiologic and clinical implications

Thyrotropin releasing hormone is thought to be a tonic stimulator of the pituitary TSH secretion regulating the setpoint of the thyrotrophs to the suppressive effect of thyroid hormones. The peptide stimulates the release of normal and elevated prolactin. ACTH and GH may increase in response to exogenous TRH in pituitary ACTH and GH hypersecretion syndromes and in some extrapituitary diseases. The pathophysiological implications of extrahypothalamic TRH in humans are essentially unknown. The TSH response to TRH is nowadays widely used as a diganostic amplifier in thyroid diseases being suppressed in borderline and overt hyperthyroid states and increased in primary thyroid failure. In hypothyroid states of hypothalamic origin, TSH increases in response to exogenous TRH often with a delayed and/or exaggerated time course. But in patients with pituitary tumors and suprasellar extension TSH may also respond to TRH despite secondary hypothyroidism. This TSH increase may indicate a suprasellar cause for the secondary hypothyroidism, probably due to portal vessel occlusion. The TSH released in these cases is shown to be biologically inactive

Human Monoclonal Antibodies Neutralizing Cytomegalovirus (CMV) for Prophylaxis of CMV Disease: Report of a Phase I Trial in Bone Marrow Transplant Recipients

The safety and pharmacokinetics of the two neutralizing human IgG1 monoclonal antibodies to cytomegalovirus (CMV) SDZ89-104 and 89-109 in bonemarrowtransplant (BM1)recipients was assessed in an open phase I trial. Thirteen patients, 8 seropositive and 5 seronegative for CMV, were treated with allogeneic or autologous bone marrow transplantation. SDZ 89-104 was given to 5 and SDZ 89-109 to 8 patients. Patients were divided into high-and low-dose groups. A fixed prestudy dose of 0.1 mg/kg was given 4 days before BMT. On days 3, 17, 31,45, 59, and 73, patients were treated with either 0.5 or 2 mg/kg of the respective antibody. Results indicate that doses of 2 mg/kg of SDZ 89-104 or SDZ 89-109 in alternating weeks can be safely administered to BMT patients. Serum trough levels measured by antiidiotype ELISA were ∼10 µg/ml after administration of 0.5 mg/kg and ∼50 µg/ml after treatment with 2 mg/kg of SDZ 89-104 or SDZ 89-109. High serum levels defined by antiidiotype ELISA techniques closely paralleled increased neutralizing activity. Serum half-lives calculatedfrom these data were ∼6 day

Combined Use of Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis.

Immune-based assays are promising tools to help to formulate diagnosis of active tuberculosis. A multiparameter flow cytometry assay assessing T-cell responses specific to Mycobacterium tuberculosis and the combination of both CD4 and CD8 T-cell responses accurately discriminated between active tuberculosis and latent infection